Wedbush Reiterates Outperform on argenx, Maintains $1000 Price Target

Wedbush analyst David Nierengarten reiterates argenx (NASDAQ:ARGX) with a Outperform and maintains $1000 price target.

argenx to Share New VYVGART Data for Autoimmune Diseases at EULAR

argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the presentation of new data evaluating

Wells Fargo Maintains Overweight on argenx, Raises Price Target to $1291

Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1260 to $1291.

Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today

Evercore ISI Group Maintains Outperform on argenx, Raises Price Target to $1059

Evercore ISI Group analyst Gavin Clark-Gartner maintains argenx (NASDAQ:ARGX) with a Outperform and raises the price target from $1007 to $1059.

Argenx Eyes Larger Patient Pool Following Expanded FDA Nod For Lead Drug For Neuromuscular Disease

Argenx shares rise after FDA expands VYVGART approval to all adult gMG patients, widening the drug's market opportunity.

argenx Announces FDA Approval Expanding VYVGART And VYVGART Hytrulo Label To Treat All Serotypes Of Generalized Myasthenia Gravis Based On ADAPT SERON Phase 3 Results

VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple

Guggenheim Maintains Buy on argenx, Raises Price Target to $1135

Guggenheim analyst Yatin Suneja maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $1120 to $1135.

Wells Fargo Maintains Overweight on argenx, Raises Price Target to $1260

Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1247 to $1260.

argenx Q1 EPS $5.52 Beats $5.42 Estimate, Sales $1.313B Miss $1.314B Estimate

argenx (NASDAQ:ARGX) reported quarterly earnings of $5.52 per share which beat the analyst consensus estimate of $5.42 by 1.85 percent. This is a 113.95 percent increase over earnings of $2.58 per share from the same